Skip to search formSkip to main contentSkip to account menu

apatinib

Known as: 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1) 
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (1)

Pyridines

Narrower (1)

YN968D1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
4507Background: Chinese patients (pts) account for more than 50% of hepatocellular carcinoma (HCC) cases in the world and have… 
2018
2018
Clinical response to apatinib monotherapy in advanced non‐small cell lung cancer
Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR‐2, exerts both antiangiogenesis and antiproliferation effects… 
Highly Cited
2017
Highly Cited
2017
Apatinib has anti-tumor effects and induces autophagy in colon cancer cells
Objective(s): Apatinib recently has been used to treat patients with gastric cancer, but the function of apatinib in colon cancer… 
Review
2017
Review
2017
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review
Chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer (PC), and has serious side… 
2017
2017
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced… 
2017
2017
Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
BackgroundApatinib, a third-line or later treatment for advanced gastric cancer (aGC), was shown to improve overall survival and… 
Review
2016
Review
2016
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer
Abstract Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been… 
2016
2016
Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have… 
Review
2013
Review
2013
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
2011
2011
A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.
4019 Background: Apatinib at a daily dose of 850mg was tolerable from our phase I study. The objective of this study was to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)